NCT00001296View on ClinicalTrials.gov

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

February 29, 1992

Study Completion Date

October 31, 2000

Conditions
Melanoma
Interventions
DRUG

melphalan

DRUG

tumor necrosis factor

DRUG

interferon-gamma

PROCEDURE

hyperthermic isolated limb perfusion

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH